Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
Alterity Therapeutics Raises A$40.0 million in Placement
Alterity Therapeutics Limited (NASDAQ: ATHE) was downgraded by analysts at Benchmark Co. from a "speculative buy" rating to a "hold" rating.